MANAC Chemical Partners (4360) FY2026 Q3 Earnings Report

Quick View

Executive Summary

For the cumulative Q3 period of the fiscal year ending March 2026, the Company turned profitable at the operating level due to substantial earnings improvement in addition to revenue growth. Revenue was ¥8.30B (¥7.06B in the same period last year, +17.5% YoY), while Operating Income was ¥0.62B (an Operating Loss of ¥0.18B in the same period last year). Ordinary Income was ¥0.68B and Net Income was ¥0.60B, with both turning profitable from losses in the same period last year. In addition to revenue growth, a lower cost-of-sales ratio and controlled SG&A expenses increased operating leverage, while improved profitability in the Fine Chemicals Business led the overall return to profitability.

Factors Affecting Performance

【Revenue】Revenue increased 17.5% YoY to ¥8.30B. By segment, the Fine Chemicals Business recorded the largest increase at ¥3.90B (47.0% of total, +32.3% YoY), followed by the Flame Retardants Business at ¥3.31B (39.9% of total, +8.2%) and the Health Support Business at ¥1.08B (13.0% of total, +2.9%). While all segments posted revenue growth, the high growth rate of the Fine Chemicals Business drove overall revenue growth.

【Earnings】The gross profit margin improved significantly to 23.4% from 16.7% in the same period last year, with the decline in the cost-of-sales ratio contributing to gross profit expansion. SG&A expenses decreased 3.3% YoY to ¥1.32B, and expense control amid revenue growth contributed to an improvement in the operating margin from -2.6% in the same period last year to 7.5% in the current period. Ordinary Income was ¥0.68B. Non-operating income, including interest and dividend income of ¥0.06B, was an upward factor, while a foreign exchange loss of ¥0.02B was a deduction factor. Extraordinary Income of ¥0.08B included a gain on the sale of shares in a subsidiary of ¥0.07B, a temporary factor accounting for approximately 13% of Net Income of ¥0.60B. Accordingly, the current period saw increases in both revenue and earnings, with improved core business profitability being the primary driver of the earnings turnaround.

Segment Analysis

The Fine Chemicals Business recorded Revenue of ¥3.90B (+32.3% YoY), segment profit of ¥0.96B, and a profit margin of 24.6% (16.8% in the same period last year), demonstrating the highest profitability among the three businesses and making the largest contribution to consolidated Operating Income. The Flame Retardants Business recorded Revenue of ¥3.31B (+8.2%), while segment profit increased approximately 4.9-fold YoY to ¥0.38B, with the profit margin improving significantly from 2.5% to 11.5%. The Health Support Business recorded Revenue of ¥1.08B (+2.9%), segment profit of ¥0.09B (+2.1-fold), and an improved profit margin of 8.0% from 3.9%. Against total segment profit of ¥1.43B, Company-wide expenses of ¥0.81B (+¥0.01B YoY) were deducted, resulting in consolidated Operating Income of ¥0.62B. Company-wide expenses are increasing only moderately, and maintaining profitability in the core businesses while controlling Company-wide expenses relative to revenue will be key to improving profit margins going forward.

Key Financial Indicators

【Profitability】The operating margin improved to 7.5% from negative 2.6% in the same period last year, while the net profit margin also turned positive at 7.3%. The gross profit margin improved to 23.4% from 16.7% in the same period last year.【Cash Quality】Cash and deposits increased to ¥3.40B from ¥2.77B in the same period last year, while accounts receivable and notes receivable stood at ¥2.52B and inventories at ¥2.11B, indicating an accumulation of working capital and funds tied up amid revenue growth.【Investment Efficiency】Annualized ROE was 7.3%, while the Equity Ratio was 76.5% (81.5% in the same period last year). The Equity Ratio declined somewhat due to profit accumulation without an equity offering and an increase in property, plant and equipment.【Financial Soundness】Liquidity remains ample, with current assets of ¥9.81B compared with current liabilities of ¥2.71B. Long-term borrowings remained limited at ¥0.43B, and financial leverage remained low.

Cash Flow Analysis

Although the cash flow statement has not been disclosed, changes in the balance sheet provide insight into fund flows. Cash and deposits increased 22.8% YoY to ¥3.40B, confirming cash generation associated with improved profitability. Meanwhile, property, plant and equipment increased by ¥0.91B from ¥1.75B in the same period last year to ¥2.66B, including an increase in construction in progress from ¥0.11B to ¥0.77B, indicating that capital expenditures are driving an increase in the asset base. Accounts receivable and notes receivable stood at ¥2.52B and inventories at ¥2.11B, indicating a possible increase in funds tied up that exceeded the increase in accounts payable from ¥1.42B to ¥1.64B. Total assets increased 14.3% YoY to ¥14.46B, with both earnings growth and expanded investment contributing to the increase in the asset base.

Earnings Quality

The core driver of current-period profit was improved profitability in the core business, with Operating Income of ¥0.62B and Ordinary Income of ¥0.68B steadily accumulated. Non-operating income consisted primarily of recurring income such as interest and dividend income of ¥0.06B, while non-operating expenses consisted primarily of a foreign exchange loss of ¥0.02B. Meanwhile, Extraordinary Income of ¥0.08B included a gain on the sale of shares in a subsidiary of ¥0.07B, a non-recurring item equivalent to approximately 13% of Net Income of ¥0.60B. Accordingly, when assessing recurring earnings power, Operating Income and Ordinary Income should be the primary focus, while noting that Net Income includes a temporary upward effect. Comprehensive Income was ¥0.80B, slightly exceeding Net Income of ¥0.60B, primarily due to a ¥0.19B increase in the valuation difference on securities. However, this item should be distinguished from the Company’s underlying earnings power.

Earnings Forecast and Guidance

Progress toward the full-year earnings forecast was 77.6% for Revenue (forecast: ¥10.70B), 103.2% for Operating Income (forecast: ¥0.60B), 105.4% for Ordinary Income (forecast: ¥0.65B), and 100.5% for Net Income (forecast: ¥0.60B). Revenue exceeded the standard progress benchmark of approximately 75%, while earnings had already surpassed the full-year forecast as of the cumulative Q3 period. The earnings forecast was revised during the current quarter, reflecting an upward revision from the initial plan. While Revenue of ¥2.40B must be added in Q4, Net Income includes the non-recurring gain on the sale of shares in a subsidiary of ¥0.07B. Therefore, it is appropriate to assess potential full-year upside primarily based on Operating Income and Ordinary Income.

Shareholder Returns

The Q2 dividend was ¥5.00 per share, and the full-year dividend forecast is ¥10.00 per share. Based on cumulative current-period Net Income of ¥0.60B, the calculated Payout Ratio is approximately 12.4% (estimated using 8,174 thousand shares, calculated by deducting 451 thousand treasury shares from 8,625 thousand issued shares), indicating a low dividend burden relative to earnings. No revision was made to the dividend forecast during the current quarter. The financial base of ¥3.40B in cash and deposits and an Equity Ratio of 76.5% supports the Company’s ability to pay dividends. Meanwhile, capital expenditures, including ¥0.77B in construction in progress, and the accumulation of working capital remain priorities for capital allocation.

Risk Factors

1. Business concentration risk: The Fine Chemicals Business accounts for 47.0% of total revenue and 67.2% of total segment profit, creating a structure in which demand and price fluctuations in this business have a significant impact on consolidated performance.

2. Accumulation of working capital: Accounts receivable and notes receivable of ¥2.52B and inventories of ¥2.11B (including finished-goods inventories of ¥2.11B) have increased, creating risks of funds being tied up amid revenue growth, as well as risks related to inventory sales absorption and valuation losses.

3. Risk of monetizing capital expenditures: Construction in progress increased from ¥0.11B in the same period last year to ¥0.77B, accounting for 28.8% of property, plant and equipment. The timing of completion and certainty of monetizing the investment after commencement of operations will affect capital efficiency going forward.

Industry Benchmark (Reference; Compiled by the Company)

Profitability and Returns

The operating margin is slightly below the industry median, while the net profit margin exceeds it, indicating that the Company’s earnings structure is generally at an average level within the industry.

Growth and Capital Efficiency

Revenue growth is significantly above the industry median, indicating a high level of growth within the industry.

※Source: Compiled by the Company

Key Points from the Earnings Results

1. As indicated by the 17.5% increase in Revenue and the turnaround from an operating loss to profitability, the current period represents a clear phase of improvement in core business profitability. Improved profitability in the Fine Chemicals Business and the improvement in the Flame Retardants Business profit margin from 2.5% to 11.5% were the primary drivers of the turnaround.

2. Net Income includes a gain on the sale of shares in a subsidiary of ¥0.07B, meaning that part of the 100.5% full-year progress reflects a non-recurring upward effect. For an assessment of recurring earnings power, it is appropriate to focus primarily on Operating Income (103.2% progress) and Ordinary Income (105.4% progress).

3. Increases in accounts receivable and inventories, along with the expansion of construction in progress to ¥0.77B, indicate changes in fund efficiency amid revenue growth and expanded investment. Progress in collecting receivables, reducing inventories, and bringing investments into operation will be key monitoring points going forward.

Theoretical Share Price (Reference Value)

Sensitivity: ¥1,140–¥1,206 for a ±1% change in the cost of equity, and ¥1,166–¥1,176 for a change of ±0.1 in ω.

Notes:

• Because Net Income progress against the full-year forecast (100%) exceeds the standard level (75%), forecast EPS has been adjusted upward within a maximum range of +10% (because companies with progress ahead of plan tend to exceed forecasts; the adjustment may be excessive for businesses with strong seasonality).
• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end are used (there is a timing difference from the full-year forecast).
• Because net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type; explicit 5-year fade) / Interest rate reference month: 2026-08 / This is a mechanically calculated value based solely on publicly disclosed data; it is not a forecast of the market share price or a recommendation of any specific investment action, and does not forecast or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. Industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional as necessary.

---End of Report---